Promising Developments in PMV Pharmaceuticals’ PYNNACLE Phase 2 Trial Boost Buy Rating
I'm PortAI, I can summarize articles.
TD Cowen analyst Yaron Werber has maintained a Buy rating on PMV Pharmaceuticals (PMVP) stock, citing promising developments in the PYNNACLE Phase 2 trial for ovarian cancer, which reported a 46% overall response rate and an 8-month median duration of response. The company has a strong financial position with $129 million in cash, supporting potential drug application filings. H.C. Wainwright also reiterated a Buy rating with a $5.00 price target, indicating strong investment potential for PMVP.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments